XSC
ABBV icon

X-Square Capital’s AbbVie ABBV Stock Holding History

X-Square Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.09M Sell
14,214
-1,194
-8% -$265K 1.04% 25
2025
Q4 		$3.52M Sell
15,408
-521
-3% -$119K 1.15% 25
2025
Q3 		$3.69M Buy
15,929
+255
+2% +$51.9K 1.15% 22
2025
Q2 		$2.91M Buy
15,674
+133
+0.9% +$24.7K 1.05% 30
2025
Q1 		$3.26M Buy
15,541
+689
+5% +$134K 1.4% 18
2024
Q4 		$2.64M Buy
14,852
+142
+1% +$26.1K 1.08% 31
2024
Q3 		$2.9M Buy
14,710
+625
+4% +$117K 1.28% 26
2024
Q2 		$2.42M Sell
14,085
-171
-1% -$28.3K 1.12% 30
2024
Q1 		$2.51M Buy
14,256
+8,981
+170% +$1.55M 1.19% 29
2023
Q4 		$817K Buy
5,275
+1,051
+25% +$153K 0.45% 73
2023
Q3 		$569K Hold
4,224
– – 0.38% 82
2023
Q2 		$569K Buy
4,224
+1,950
+86% +$286K 0.38% 82
2023
Q1 		$362K Buy
2,274
+8
+0.4% +$1.22K 0.21% 113
2022
Q4 		$366K Buy
+2,266
New +$347K 0.21% 119

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

X-Square Capital's ABBV Position: Q1 2026 in Review

X-Square Capital reduced its AbbVie (ABBV) stake by 7.7% in Q1 2026, selling an estimated $265K and leaving 14,214 shares worth $3.09M. The position accounts for 1.04% of the portfolio, ranked #25.

X-Square Capital first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.69M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • X-Square Capital held 14,214 shares of AbbVie worth $3.09M as of Q1 2026.
  • X-Square Capital sold 1,194 AbbVie shares in Q1 2026, an estimated $265K.
  • AbbVie made up 1.04% of X-Square Capital's portfolio in Q1 2026, its #25 holding.
  • X-Square Capital first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • X-Square Capital's AbbVie position peaked at $3.69M in Q3 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on X-Square Capital's 13F filing for Q1 2026, filed 15 May 2026.